Moderna (MRNA): Bridgewater Associates added to its stake +60K shares
Bridgewater Associates added to its stake in Moderna, per its Q1 2026 13F.
- 75K
- Shares reported · +60K vs prior quarter
- 0.02%
- Disclosed portfolio weight
- $3.8M
- Reported value
- Holdings as of
- Mar 31, 2026
- Filed
- May 15, 2026
What stands out in this filing
- 15,181 shares in Q4 2025, 74,822 now (+392.9% in share count).
- Reported at $3.8M, 0.02% of the portfolio value in this 13F filing.
- 19 other tracked managers reported the same kind of change for Q1 2026.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
The company's last weighty Form 8-K report up to this date: changed its bylaws, charter or fiscal year, 9 days earlier (May 6, 2026). The first one after it: changed a top executive or board member, 52 days later (Jul 6, 2026).
- 5% stakeThe Vanguard Group reported a passive stake (13G)
- 5% stakeVanguard Capital Management reported a passive stake (13G) of 6.5%
- Company filing · Form 8-K · ResultsReported its results
- InsiderDirector sold ~$265K of MRNA shares in the open market
- Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote
- InsiderOfficer sold ~$2.58M of MRNA shares in the open market
What came next
- InsiderDirector sold ~$434K of MRNA shares in the open market
- InsiderOfficer sold ~$174K of MRNA shares in the open market
- InsiderOfficer sold ~$2.74M of MRNA shares in the open market
- Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On July 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), appointed Michael McDonnell to the Board, effective July 8, 2026.”
- InsiderOfficer sold ~$3.61M of MRNA shares in the open market
- 5% stakeBAILLIE GIFFORD & CO reported a passive stake (13G) of 4.6%
- Company filing · Form 8-K · ResultsReported its results
- Insider · 1 personInsiders: 4 sales (~$28.7M)
- 5% stakeFMR LLC reported a passive stake (13G) of 13.1%
- 5% stakeCapital World Investors reported a passive stake (13G) of 5.6%
- Congress · 1 personMembers of Congress: 1 purchase, 1 sale
- Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
- InsiderOfficer sold ~$486K of MRNA shares in the open market
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Moderna
For Moderna, OQRO holds 19 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRNA page.
How this filing works
Explore the data
Common questions
What does this filing report about Moderna (MRNA) stock?
Bridgewater Associates added to its stake in Moderna, per its Q1 2026 13F. Now 75K shares, $3.8M reported value, 0.02% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Mar 31, 2026. Filed: May 15, 2026.
What stands out in this filing?
15,181 shares in Q4 2025, 74,822 now (+392.9% in share count). Reported at $3.8M, 0.02% of the portfolio value in this 13F filing. 19 other tracked managers reported the same kind of change for Q1 2026.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Moderna recently?
For Moderna, OQRO holds 19 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the MRNA page.
Does this mean MRNA stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Moderna
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 144Nov 17, 2026
- SEC Form 13F-HRNov 16, 2026
Everything OQRO holds on this company is on its MRNA page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
